Skip to main content

Advertisement

SpringerLink
Log in

Acute optic neuritis

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

In acute monosymptomatic optic neuritis, treatment with oral prednisone alone should be avoided. Therapy with intravenous methylprednisolone (1 g/day for 3 days) followed by 11 days of oral prednisone (1 mg/kg with a short taper) should be considered instead. This is particularly true if a patient considers accelerated visual recovery to be particularly urgent or if magnetic resonance imaging (MRI) demonstrates three or more signal abnormalities consistent with demyelination. In patients without a diagnosis of clinically definite multiple sclerosis (CDMS), an MRI should be considered to assess the prognosis for developing multiple sclerosis (MS) and to eliminate other causes of optic neuropathy. Foregoing an MRI or steroid treatment is an acceptable option. Chest x-ray, blood tests, and lumbar puncture are not necessary in evaluating patients with typical clinical features of optic neuritis. These tests may be appropriate, however, for patients who are about to undergo corticosteroid therapy, which could complicate or mask an unrecognized condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Beck RW: The Optic Neuritis Treatment Trial. Arch Ophthalmol 1988, 106:1051–1053.

    PubMed  CAS  Google Scholar 

  2. Optic Neuritis Study Group: The clinical profile of acute optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991, 109:1673–1678. The clinical data of 457 patients recruited for the ONTT.

    Google Scholar 

  3. Beck RW, Cleary PA, Anderson MA, et al.: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581–588. The report of the National Eye Institute Class I study reviewing prednisone, placebo, and intravenous methylprednisolone treatment strategies in 457 patients who were followed for 6 months after therapy. Much of what we know about the dangers of using prednisone alone in ON is based on this work.

    Article  PubMed  CAS  Google Scholar 

  4. Francis DA, Compston DAS, Batchelor JR, McDonald WI: A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow up. J Neurol Neurosurg Psychiatr 1987, 50:758–765.

    PubMed  CAS  Google Scholar 

  5. Rizzo JF, Lessell S: Risk of developing multiple sclerosis after uncomplicated optic neuritis. A long-term prospective study. Neurolog 1988, 38:185–190. A classic review of the risk of developing multiple sclerosis after ON. Follow-up was up to 15 years.

    Google Scholar 

  6. Sandberg-Wolheim M, Bynke H, Cronqvist S, et al.: A longterm prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 1990, 27:386–393.

    Article  Google Scholar 

  7. Nikoskelainen E: Later course and prognosis of optic neuritis. Acta Ophthalmol 1975, 53:273–291.

    CAS  Google Scholar 

  8. Kupersmith MJ, Nelson JI, Seiple WH, et al.: The 20/20 eye in multiple sclerosis. Neurolog 1983, 33:1015–1020.

    CAS  Google Scholar 

  9. Hutchinson WM: Acute optic neuritis and the prognosis for multiple sclerosis. J Neurol Neurosurg Psychiatr 1976, 39:283–289.

    PubMed  CAS  Google Scholar 

  10. Hely MA, McManis PG, Doran TJ, et al.: Acute optic neuritis: a prospective study of risk factors for multiple sclerosis. J Neurol Neurosurg Psychiatry 1986, 498:1125–1130.

    Google Scholar 

  11. Perkin GD, Rose FC: Optic Neuritis and Its Differential Diagnosis. New York: Oxford; 1979:226–248.

    Google Scholar 

  12. Ebers GC: Optic neuritis and multiple sclerosis. Arch Neurol 1985, 42:702–704.

    PubMed  CAS  Google Scholar 

  13. Sanders EA, Volkers AC, van der Poel JC, van Lith GH: Estimation of visual function after optic neuritis; a comparison of clinical tests. Br J Ophthalmol 1986, 70:918–924.

    PubMed  CAS  Google Scholar 

  14. Fleishman JA, Beck RW, Linares OA, Klein JW: Deficits in visual function after resolution of optic neuritis. Ophthalmology 1987, 94:1029–1035.

    PubMed  CAS  Google Scholar 

  15. Budning AS, Gans M, Filer R, Greenberg S: Visual function after optic neuritis: a preliminary study. Can J Ophthalmol 1991, 26:18–20.

    PubMed  CAS  Google Scholar 

  16. Optic Neuritis Treatment Group: Visual function 5 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 1997, 115:1545–1552. This Class I study documented the 5-year follow-up of ONTT patients based on the initial funduscopic appearance. It revealed that the worse the optic disk swelling (papillitis) at entry, the lower the chance of developing MS. No patient with early retinitis (eg, a macular scar) developed MS within 5 years.

    Google Scholar 

  17. Jacobs L, Munschauer FE, Kaba SE: Clinical and magnetic resonance imaging in optic neuritis. Neurology 1991, 41:15–19.

    PubMed  CAS  Google Scholar 

  18. Frederiksen JL, Larsson GBW, Henriksen O, Elesen J: Magnetic resonance imaging of the brain in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 1989, 80:512–517.

    PubMed  CAS  Google Scholar 

  19. Beck RW, Arrington J, Murtagh FR, et al.: Brain MRI in acute optic neuritis experience of the optic neuritis study group. Arch Neurol 1993, 8:841–846. Interesting review of the MRI studies done in the ONTT. This includes a classification scheme for level of abnormality.

    Google Scholar 

  20. Trauzettel-Klosinski S, Axmann D, Diener HC: The Tubingen study on optic neuritis treatment: a prospective, randomized and controlled trial. Clin Visual Sci 1993, 8(4):385–394. This class II study compared larger doses of oral methylprednisolone than the ONTT to a placebo and found it to be of no value in ON.

    Google Scholar 

  21. Gould ES, Bird AC, Leaver PK, McDonald WI: Treatment of optic neuritis by retrobulbar injection of triamcinolone. Br Med J 1977, 1:1485–1497.

    Article  Google Scholar 

  22. Ershkovich IG, Gol’dfel’d NG, Koza RI: The value of glycerin and retrobulbar injections of hydrocortisone in the treatment of neuritis of the optic nerve. Oftalmol Zh 1969, 24(2):322–328.

    Google Scholar 

  23. Rawson MD, Liversedge LA, Goldfarb G, McGill BA: Treatment of acute retrobulbar neuritis with corticotrophin. Lancet 1966, 2:1044–1046.

    Article  PubMed  CAS  Google Scholar 

  24. Rawson MD, Liversedge LA: Treatment of retrobulbar neuritis with corticotrophin. Lancet 1969, 2:222.

    Article  PubMed  CAS  Google Scholar 

  25. Spoor TC, Rockwell DL: Treatment of optic neuritis with intravenous megadose corticosteroids. A consecutive series. Ophthalmology 1998, 95(1):131–134.

    Google Scholar 

  26. van Engelen BG, Hommes OR, Pinckers A, et al.: Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992, 32(6):834–835.

    Article  PubMed  Google Scholar 

  27. Huang SY, Zeng YC: Clinical observations on treatment of disorders of the optic nerve by acupuncture. J Tradit Chin Med 1985, 5(3):187–190.

    PubMed  CAS  Google Scholar 

  28. Glaser GH, Merritt HH: Effects of corticotrophin (ACTH) and cortisone on disorders of the nervous system. JAMA 1952, 148:898–904.

    CAS  Google Scholar 

  29. Quinn JR, Wolfson WQ: Improved results from individualized intensive hormonal treatment in certain eye diseases reported to respond poorly to ACTH or cortisone. Univ Mich Med Bull 1952, 18:1–21.

    PubMed  CAS  Google Scholar 

  30. Spoor TC: Treatment of optic neuritis with megadose corticosteroids. J Clin Neuro-ophthalmol 1986, 6:137–143.

    CAS  Google Scholar 

  31. Kapoor R, Miller DH, Jones SJ, et al.: Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurolog 1998, 50:230–237. This class II study showed that IVMP was of no value in improving visual outcome in patients with lesions in the optic canal.

    Article  CAS  Google Scholar 

  32. Beck RW, Cleary PA, Trobe JD, et al.: The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993, 329:1764–1769. A Class I study documenting the 2-year follow-up of the ONTT, evaluating 389 patients with ON longitudinally. In patients with an MRI showing three or more white matter lesions, IVMP provided a statistically significant protective effect for about 2 years against subsequent neurologic events (consistent with MS) compared with an oral placebo.

    Article  PubMed  CAS  Google Scholar 

  33. Chrousos GA, Kattah JC, Beck RW, et al.: Side effects of glucocorticoid treatment: experience of the Optic Neuritis Treatment Trial. JAMA 1993, 269:2110–2112.

    Article  PubMed  CAS  Google Scholar 

  34. Beck RW, Cleary PA, et al.: Optic Neuritis Treatment Trial: one-year follow-up results. Arch Ophthalmol 1993, 111:773–775.

    PubMed  CAS  Google Scholar 

  35. Beck RW, Trobe JD: The Optic Neuritis Treatment Trial: putting the results in perspective. J Neuroophthalmol 1995, 15:131–135.

    PubMed  CAS  Google Scholar 

  36. Optic Neuritis Study Group: The 5 year risk of MS after optic neuritis. Neurology 1997, 49:1404–1413. This Class I study reports the Longitudinal Optic Neuritis Study, the 5-year outcome of the ONTT patients. It documents the importance of MRI in determining the 5-year prognosis for developing MS in patients with ON. If the MRI shows three or more white matter lesions, the chance of developing MS is 51% by 5 years. If the MRI is normal, however, the chance of developing MS by 5 years is 16%.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Clinical Neuroscience and Ophthalmology, A-217 Michigan State University Clinical Center, Colleges of Osteopathic and Human Medicine, 138 Service Road, 48823, E. Lansing, MI, USA

    David I. Kaufman DO

Authors
  1. David I. Kaufman DO
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaufman, D.I. Acute optic neuritis. Curr Treat Options Neurol 1, 44–48 (1999). https://doi.org/10.1007/s11940-999-0031-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-999-0031-7

Keywords

Search

Navigation